Pancreas Cancer, Pancreas Cyst
Conditions
Brief summary
Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.
Interventions
OTHERLateral Flow Assay (LFA)
Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
Sponsors
Mayo Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
17 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy. * Patients without pancreas cancer. * Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer. * Healthy adults with blood specimens in an existing biobank. * Patients with pancreatic cystic lesions. * Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions.
Exclusion criteria
* Prior treatment for pancreas cancer. * Unable or unwilling to give consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood | Baseline | Number of subjects with the presence and concentration of QSOX1 peptide found in the blood samples by the lateral flow assay (LFA) test |
Countries
United States
Outcome results
None listed